Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: preliminary results at 24 weeks of the DORIVIR study
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2016）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined